Back to top
more

OPKO Health (OPK)

(Delayed Data from NSDQ)

$1.26 USD

1.26
3,664,499

-0.01 (-0.79%)

Updated Aug 5, 2025 04:00 PM ET

After-Market: $1.27 +0.01 (0.79%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value F Growth A Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 36% (158 out of 246)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

HMS Holdings (HMSY) Loses 2.9% Since Q2 Earnings Release

by Zacks Equity Research

HMS Holdings (HMSY) witnessed revenue growth in COB segment in Q2.

Zacks Equity Research

Chemed's (CHE) VITAS Business Strong Amid Coronavirus Crisis

by Zacks Equity Research

Amid the pandemic scenario, Chemed's (CHE) VITAS and Roto-Rooter both have been classified as essential services.

Zacks Equity Research

AMN Healthcare (AMN) Loses 3.3% Despite Q2 Earnings Beat

by Zacks Equity Research

AMN Healthcare (AMN) gained from two of its three core operating segments in Q2.

Zacks Equity Research

PRA Health (PRAH) Q2 Earnings and Revenues Beat Estimates

by Zacks Equity Research

PRA Health's (PRAH) Data Solutions segment puts up a strong performance in Q2.

Zacks Equity Research

Surmodics (SRDX) Q3 Earnings and Revenues Beat Estimates

by Zacks Equity Research

Surmodics (SRDX) registered revenue growth in each of its core units viz. In Vitro Diagnostics and Medical Device in Q3.

Zacks Equity Research

Has OPKO Health (OPK) Outpaced Other Medical Stocks This Year?

by Zacks Equity Research

Is (OPK) Outperforming Other Medical Stocks This Year?

Zacks Equity Research

Nevro (NVRO) Q2 Loss Narrower than Expected, Revenues Beat

by Zacks Equity Research

Nevro's (NVRO) domestic and international revenues declined on a year-over-year basis in Q2.

Zacks Equity Research

Varian (VAR) Earnings and Revenues Surpass Estimates in Q3

by Zacks Equity Research

Varian's (VAR) Proton Solutions unit saw revenue growth in Q3.

Zacks Equity Research

ABIOMED (ABMD) Earnings and Revenues Beat Estimates in Q1

by Zacks Equity Research

ABIOMED's (ABMD) flagship Impella saw decline in revenues internationally and within the United States, in Q1.

Zacks Equity Research

Becton Dickinson (BDX) Earnings Surpass Estimates in Q3

by Zacks Equity Research

Within the United States, Becton Dickinson's (BDX) Diagnostic Systems unit witnessed strong revenue growth in Q3.

Zacks Equity Research

Luminex (LMNX) Q2 Earnings Beat Estimates, Revenues Miss

by Zacks Equity Research

Luminex (LMNX) witnessed total sample-to-answer molecular diagnostics revenue growth in Q2

Zacks Equity Research

Inogen's (INGN) Q2 Earnings Beat Estimates, Revenues Miss

by Zacks Equity Research

Inogen (INGN) saw growth in revenues within its Rental segment in Q2.

Zacks Equity Research

Pacific Biosciences (PACB) Posts Lower-Than-Expected Q2 Loss

by Zacks Equity Research

Pacific Biosciences (PACB) saw revenue decline in both its operating segments in Q2.

Zacks Equity Research

OPKO Health (OPK) is a Great Momentum Stock: Should You Buy?

by Zacks Equity Research

Does OPKO Health (OPK) have what it takes to be a top stock pick for momentum investors? Let's find out.

Zacks Equity Research

Allscripts (MDRX) Q2 Earnings and Revenues Beat Estimates

by Zacks Equity Research

Allscripts (MDRX) witnessed decline in core Client Services and Software delivery unit revenues during Q2.

Zacks Equity Research

DaVita (DVA) Earnings Beat Estimates in Q2, Revenues Miss

by Zacks Equity Research

DaVita's (DVA) dialysis services in the United States were solid in Q2.

Zacks Equity Research

NextGen Healthcare (NXGN) Tops Q1 Earnings & Revenue Estimates

by Zacks Equity Research

NextGen (NXGN) benefited from its Recurring segment in Q1.

Zacks Equity Research

OPKO Health (OPK) Q2 Earnings and Revenues Beat Estimates

by Zacks Equity Research

OPKO Health's (OPK) second-quarter results benefit from increase in RAYALDEE prescriptions.

Zacks Equity Research

OPKO Health (OPK) Q2 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

OPKO Health (OPK) delivered earnings and revenue surprises of 171.43% and 28.41%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

PerkinElmer (PKI) Q2 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

PerkinElmer's (PKI) second-quarter results benefit from growth in Diagnostics segment. However, forex remains a woe.

Zacks Equity Research

DexCom (DXCM) Q2 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

DexCom's (DXCM) second-quarter results benefit from solid segmental performance.

Zacks Equity Research

OPKO Health (OPK) to Report Q2 Earnings: What's in Store?

by Zacks Equity Research

OPKO Health's (OPK) second-quarter results are likely to reflect solid performance from Products segment and RAYALDEE.

Zacks Equity Research

Masimo (MASI) Earnings and Revenues Beat Estimates in Q2

by Zacks Equity Research

Masimo (MASI) continues to gain from key Product segment, which witnessed solid growth in Q2.

Zacks Equity Research

Ecolab (ECL) Earnings and Revenues Lag Estimates in Q2

by Zacks Equity Research

Ecolab's (ECL) second-quarter results reflect weakness in the Global Industrial and Institutional segments.

Zacks Equity Research

OPKO Health (OPK) Gains As Market Dips: What You Should Know

by Zacks Equity Research

In the latest trading session, OPKO Health (OPK) closed at $5.60, marking a +0.72% move from the previous day.